Program
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863
Its studies are mostly in Stomach Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Jun 16, 20231 company-led study, 1 open or runningNext primary completion: Mar 16, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Jun 16, 2023 | Jun 16, 2023 | Mar 16, 2029phase 2 · NCT06005493 |
- Named in AstraZeneca’s own pipeline as
AZD5863
, phase 1, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2023First study: phase 2 study in Stomach NeoplasmsFirst studyNCT06005493 · 392 planned · United States, China, France and more
- Sep 25, 2026Primary completion moved from 2027-07-16 to 2029-03-16Date moved laterphase 2 · +20 months · NCT06005493
Ahead
- Mar 16, 2029Primary completion: phase 2 study in Stomach NeoplasmsNCT06005493
TargetBeta
“An affinity-optimized T-cell engaging (TCE) and human bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administrat…”NCIt, read by Claude
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06005493Stomach Neoplasms · United States, China, France and more | 2 | Recruiting | Mar 16, 2029 | 392 |
How it is read
Names in the registry
- “AZD5863”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.